Enstar Group Ltd
Change company Symbol lookup
Select an option...
ESGR Enstar Group Ltd
HCFT Hunt Companies Finance Trust Inc
BHV BlackRock Virginia Municipal Bond Trust
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
Go

Financials : Insurance | Small Cap Growth
Based in Bermuda
Company profile

Enstar Group Limited is an insurance group that offers capital release solutions and specialty underwriting capabilities through its network of group companies in Bermuda, the United States, the United Kingdom, Continental Europe, Australia and other international locations. The Company's segments include Non-Life Run-Off, Atrium, StarStone, and Life and Annuities. The Non-life Run-off segment comprises the operations of its subsidiaries that are running off their property and casualty and other non-life lines of business. The Atrium segment underwrites specialist marine, energy, aerospace, non-marine and liability classes. The StarStone segment offers a range of property, casualty and specialty insurance products. The Life and Annuities Segment consists of the operations managing the Company's closed-block of life and annuity business, and its life settlements business.

Closing Price
$178.50
Day's Change
0.92 (0.52%)
Bid
--
Ask
--
B/A Size
--
Day's High
180.87
Day's Low
178.02
Volume
(Heavy Day)
Volume:
43,938

10-day average volume:
30,446
43,938

SVB analysts downgrade Moderna's stock, citing 'competitive pressure' from other COVID vaccine developers

8:20 am ET September 8, 2020 (MarketWatch)
Print

Analysts at SVB Leerink downgraded shares of Moderna Inc. (MRNA) to underperform from market perform, citing growing "competitive pressure" from other developers of COVID-19 vaccines. Shares of Moderna were down 7.3% in premarket trading on Tuesday. The analysts said it's still likely that the Moderna's coronavirus vaccine candidate will be authorized by the Food and Drug Administration in the fourth quarter of this year "but speed to market has fallen behind competitors." Unlike other drugmakers developing experimental COVID-19 vaccines, such as Johnson & Johnson (JNJ) and Pfizer Inc. (PFE), Moderna does not have any other approved products to buffer the company's revenue-earning potential. Moderna's stock has soared 220.0% so far this year, while the S&P 500 has gained 6.0%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 08, 2020 08:20 ET (12:20 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.